Keyphrases
Antibody Response
100%
SARS-CoV-2 Infection
100%
COVID-19
66%
Neutralizing Antibodies
66%
Titre
33%
Disease Onset
33%
Symptom Onset
33%
Acute Phase
33%
Convalescent Plasma
33%
Antibody Dynamics
33%
Public Health
16%
Cross-reactivity
16%
Mild Infection
16%
Methodological Limitations
16%
Asymptomatic Infection
16%
Serosurveillance
16%
Statistical Analysis
16%
Comprehensive Assessment
16%
Hospitalized Patients
16%
MEDLINE
16%
Embase
16%
Cross-neutralization
16%
Protective Immunity
16%
Disease Severity
16%
Demographic Characteristics
16%
Humoral Immune Response
16%
Mild Disease
16%
Serological Assay
16%
Novel Pathogen
16%
Disease Control Policy
16%
Method Study
16%
National Cohort Study
16%
Self-reported Outcomes
16%
Arbitration
16%
Area of Uncertainty
16%
Recovery Phase
16%
Public Health Evidence
16%
Plateaued
16%
Long-term Patterns
16%
Severe Acute Respiratory Syndrome 2
16%
Immediate Recovery
16%
Multi-tool
16%
Quality Appraisal
16%
Coronaviridae
16%
Clinical Classification
16%
Medicine and Dentistry
Infection
100%
Antibody Response
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Systematic Review
100%
Neutralizing Antibody
66%
Diseases
66%
Public Health
33%
COVID-19
16%
Immunoglobulin M
16%
Cohort Analysis
16%
Base
16%
Pathogen
16%
Severe Acute Respiratory Syndrome
16%
Neutralization
16%
Study Participant
16%
Coronaviridae
16%
Subclinical Infection
16%
Cross Reaction
16%
Disease Severity
16%
Humoral Immunity
16%
DNA Template
16%
Nursing and Health Professions
Infection
100%
Severe Acute Respiratory Syndrome
100%
Systematic Review
100%
Neutralizing Antibody
80%
Diseases
60%
Nutrition Policy
40%
Cohort Analysis
20%
Base
20%
Antibody Titer
20%
Disease Control
20%
Asymptomatic Infection
20%
Immunoglobulin M
20%
Embase
20%
Study Participant
20%
Disease Severity
20%
Animal Experiment
20%
Clinical Classification
20%
Immunology and Microbiology
Antibody Response
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Neutralizing Antibody
66%
Dynamics
50%
Blood Plasma
33%
Cross-Reactivity
16%
Antibody Titer
16%
Humoral Immunity
16%
Infectious Agent
16%
Immunoglobulin M
16%
COVID-19
16%
Neutralization
16%
Severe Acute Respiratory Syndrome
16%
DNA Template
16%
Embase
16%
Coronaviridae
16%
Animal Experiment
16%
Clinical Classification
16%
Neuroscience
SARS Coronavirus
100%
Neutralizing Antibody
100%
Blood Plasma
50%
In Vivo
25%
Immunoglobulin M
25%
DNA Template
25%
Coronaviridae
25%
Humoral Immunity
25%
Food Science
Nutrition Policy
100%
Immunoglobulin M
50%